430 related articles for article (PubMed ID: 33918147)
1. Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle.
Augustus E; Zwaenepoel K; Siozopoulou V; Raskin J; Jordaens S; Baggerman G; Sorber L; Roeyen G; Peeters M; Pauwels P
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918147
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
Brozos-Vázquez EM; Díaz-Peña R; García-González J; León-Mateos L; Mondelo-Macía P; Peña-Chilet M; López-López R
Cancer Immunol Immunother; 2021 May; 70(5):1177-1188. PubMed ID: 33113004
[TBL] [Abstract][Full Text] [Related]
3. Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Indini A; Rijavec E; Grossi F
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918661
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.
Yang Y; Liu H; Chen Y; Xiao N; Zheng Z; Liu H; Wan J
Cell Death Dis; 2023 Mar; 14(3):230. PubMed ID: 37002211
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.
Kong W; Chen T; Li Y
Methods Mol Biol; 2023; 2695():127-143. PubMed ID: 37450116
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman P; Heeke S; Alix-Panabières C; Pantel K
Ann Oncol; 2019 Sep; 30(9):1448-1459. PubMed ID: 31228184
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.
Pérez-Callejo D; Romero A; Provencio M; Torrente M
Transl Lung Cancer Res; 2016 Oct; 5(5):455-465. PubMed ID: 27826527
[TBL] [Abstract][Full Text] [Related]
8. Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer.
Sinoquet L; Jacot W; Quantin X; Alix-Panabières C
Clin Chem; 2023 Jan; 69(1):23-40. PubMed ID: 36322450
[TBL] [Abstract][Full Text] [Related]
9. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
10. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
13. Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
Acheampong E; Spencer I; Lin W; Ziman M; Millward M; Gray E
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31262041
[TBL] [Abstract][Full Text] [Related]
14. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Honrubia-Peris B; Garde-Noguera J; García-Sánchez J; Piera-Molons N; Llombart-Cussac A; Fernández-Murga ML
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503087
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.
Michaelidou K; Agelaki S; Mavridis K
Expert Rev Mol Diagn; 2020 Mar; 20(3):335-344. PubMed ID: 32000550
[No Abstract] [Full Text] [Related]
17. Advances in liquid biopsy-based markers in NSCLC.
Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
[TBL] [Abstract][Full Text] [Related]
18. Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients.
Liu HE; Vuppalapaty M; Wilkerson C; Renier C; Chiu M; Lemaire C; Che J; Matsumoto M; Carroll J; Crouse S; Hanft VR; Jeffrey SS; Di Carlo D; Garon EB; Goldman J; Sollier E
Front Oncol; 2020; 10():572895. PubMed ID: 33117705
[TBL] [Abstract][Full Text] [Related]
19. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
[TBL] [Abstract][Full Text] [Related]
20. Cell-free DNA in non-small cell lung cancer.
Gedvilaitė V; Schveigert D; Cicėnas S
Acta Med Litu; 2017; 24(2):138-144. PubMed ID: 28845132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
